Renalytix PLC PDMR Dealing
June 13 2024 - 2:00AM
RNS Regulatory News
RNS Number : 2286S
Renalytix PLC
13 June 2024
Renalytix
plc
("Renalytix" or the "Company")
PDMR
Dealing
LONDON and SALT LAKE CITY, 13 June
2024 - Renalytix
plc (NASDAQ: RNLX) (LSE:
RENX) announces that the Board have granted
Joel Jung, the interim Chief Financial Officer, options over 60,000
ordinary shares of 0.25 pence each in the capital of the Company
("Ordinary Shares") ("Share Options").
The Share Options, which have been
issued in line with the Company's existing share option plan, have
an exercise price of £0.1625 per Ordinary Share, being the closing
price of the shares on the 11 June 2024.
One fourth (1/4th)
of the Share Options shall vest
three months after the vesting commencement date, and 1/9th of the
remaining number of Share Options shall vest monthly thereafter,
subject to continuity of service as of each such date, save that
the Option shall vest and be exercisable in full in connection with
a change in control.
For further information,
please contact:
Renalytix plc
|
www.renalytix.com
|
James McCullough, CEO
|
Via Walbrook
PR
|
|
|
Stifel (Nominated Adviser, Joint Broker)
|
Tel: 020 7710
7600
|
Alex Price / Nicholas Moore / Nick
Harland / Samira Essebiyea
|
|
|
|
Investec Bank plc (Joint Broker)
|
Tel: 020 7597
4000
|
Gary Clarence / Shalin
Bhamra
|
|
|
|
Walbrook PR Limited
Paul McManus / Alice Woodings
/
Charlotte Edgar
|
Tel: 020 7933
8780 or renalytix@walbrookpr.com
Mob: 07980
541 893 / 07407 804 654 /
07884 664
686
|
|
|
CapComm Partners
|
|
Peter DeNardo
|
Tel:
415-389-6400 or
investors@renalytix.com
|
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX)
is an in-vitro diagnostics and laboratory services company that is
the global founder and leader in the new field of bioprognosis™ for
kidney health. The leadership team, with a combined 200+ years of
healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment
for rapid progressive decline in kidney function in adult patients
with T2D and early CKD (stages 1-3). We believe that by
understanding how disease will progress, patients and providers can
take action early to improve outcomes and reduce overall health
system costs. For more information, visit
www.renalytix.com.
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
a)
|
Name
|
Joel Jung
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Interim Chief Financial
Officer
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
Renalytix plc
|
b)
|
LEI
|
213800NTOH3FK3WER551
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial
instrument, type of instrument
|
Options over ordinary shares of 0.25
pence each in the Company
|
|
|
Identification code
|
GB00BYWL4Y04
|
|
|
b)
|
Nature of the transaction
|
Grant of options over
shares
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.1625
|
60,000
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
- Aggregated volume
|
60,000
|
|
|
- Price
|
£9,750
|
|
|
e)
|
Date of the transaction
|
11 June 2024
|
f)
|
Place of the transaction
|
Outside of trading venue - off
market
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHBLLLFZQLEBBZ
Renalytix (LSE:RENX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From Jul 2023 to Jul 2024